Merck tops third-quarter estimates as Keytruda, Gardasil outperform
In short
Merck outperformed consensus financial projections during the third operating quarter behind strong business tailwinds. Strong commercial execution propelled the drugmaker past expectations during the latest reporting cycle. Demand across critical therapeutic lines underpinned the company's solid overall performance. Continued reliance on core growth drivers allowed the firm to post stronger-than-anticipated quarterly figures.
Key points
- Quarterly operational results were supported directly by strength across core corporate d…: Quarterly operational results were supported directly by strength across core corporate divisions.
- Sustained momentum in key commercial products enabled Merck to surpass overall expectatio…: Sustained momentum in key commercial products enabled Merck to surpass overall expectations.
- Third-quarter performance reflects the ongoing strength of the drugmaker's underlying pre…: Third-quarter performance reflects the ongoing strength of the drugmaker's underlying prescription portfolio.